AbbVie Inc. is ready for a fight to keep rivals away from having their piece of the biosimilar adalimumab market if reports of a price cut of 80% are anything to go by.
The discount in an, as yet, unknown market, is not expected to hurt AbbVie much financially. Even with the 80% discount, the gross margin on manufacturing Humira would be above...